Samsara BioCapital GP, LLC

CIK: 0001888829

Transaction Breakdown

Open Market Buys (P)5 (71.4%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (14.3%)

Compensation grants

Other (G, F, J, C, D, …)1 (14.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

KLRS

Kalaris Therapeutics, Inc.

10% Owner

MLYS

Mineralys Therapeutics, Inc.

10% Owner

VTVT

vTv Therapeutics Inc.

10% Owner

NGNE

Neurogene Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (7 total)

MLYS
Mineralys Therapeutics, Inc.
Mar 13, 2025
Purchase(P)
Indirect
600K shares at avg. $13.50$8.1M
NGNE
Neurogene Inc.
Nov 26, 2024
Purchase(P)
Indirect
20.7K shares at avg. $24.91$517K
NGNE
Neurogene Inc.
Nov 26, 2024
Purchase(P)
Indirect
10.8K shares at avg. $26.01$281K
NGNE
Neurogene Inc.
Nov 26, 2024
Purchase(P)
Indirect
15.2K shares at avg. $26.73$407K
NGNE
Neurogene Inc.
Nov 26, 2024
Purchase(P)
Indirect
2K shares at avg. $27.50$55K
VTVT
vTv Therapeutics Inc.
Mar 5, 2024
Other(J)
Indirect
58.8K shares-
VTVT
vTv Therapeutics Inc.
Mar 5, 2024
Award(A)
Pre- Funded Warrants (Right to Buy)
Indirect
58.9K shares-

		Type	Shares	Price		Ownership
Mar 13, 2025	MLYS Mineralys Therapeutics, Inc.	Purchase(P)	600,000	$13.50	$8,100,000	Indirect
Nov 26, 2024	NGNE Neurogene Inc.	Purchase(P)	20,748	$24.91	$516,833	Indirect
Nov 26, 2024	NGNE Neurogene Inc.	Purchase(P)	10,803	$26.01	$280,986	Indirect
Nov 26, 2024	NGNE Neurogene Inc.	Purchase(P)	15,219	$26.73	$406,804	Indirect
Nov 26, 2024	NGNE Neurogene Inc.	Purchase(P)	2,000	$27.50	$55,000	Indirect
Mar 5, 2024	VTVT vTv Therapeutics Inc.	Other(J)	58,836	-	$0	Indirect
Mar 5, 2024	VTVT vTv Therapeutics Inc.	Award(A) Pre- Funded Warrants (Right to Buy)	58,885	-	-	Indirect

1-7 of 7 transactions

About Samsara BioCapital GP, LLC

Samsara BioCapital GP, LLC (SEC CIK 0001888829) files insider reports with the SEC as 10% Owner of Kalaris Therapeutics, Inc. (KLRS), 10% Owner of Mineralys Therapeutics, Inc. (MLYS) and 10% Owner of vTv Therapeutics Inc. (VTVT). Signal8 also holds filings tied to 1 other company.

Signal8 holds 5 ownership filings by Samsara BioCapital GP, LLC (2 Form 3, 3 Form 4), filed between Nov 27, 2024 and Mar 25, 2025. Those filings report 7 transactions, from Mar 5, 2024 to Mar 13, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Samsara BioCapital GP, LLC's filings is in PALO ALTO, CA.

Recent filings by Samsara BioCapital GP, LLC

Mar 13, 2025: Open-market purchase of MLYS shares (Form 4, code P).
Nov 26, 2024: Open-market purchases of NGNE shares (4 lines, Form 4, code P).
Mar 5, 2024: Other transaction of VTVT shares (Form 4, code J).
Mar 5, 2024: Grant or award of VTVT derivative securities (Form 4, code A).

Other insiders filing for Kalaris Therapeutics, Inc. (KLRS)

Vandekop Amy O'Leary, VP, Corporate Controller
KEATING LAURIE, Director
Bayko Liisa Ann, Chief Financial Officer
Jovan-Embiricos Morana, Director
Ferrara Napoleone, Director
Hallal David, Director

How to read Form 4 transaction codes